Details

Autor(en) / Beteiligte

• Albanell, J
• Bellmunt, J
• Molina, R
• García, M
• Caragol, I
• Bermejo, B
• Ribas, A
• Carulla, J
• Gallego, O S
• Español, T
• Solé Calvo, L A

Titel

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis

Ist Teil von

• Anticancer research, 1996-03, Vol.16 (2), p.1027

Ort / Verlag

Greece

Erscheinungsjahr

1996

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The contribution of p53 and HER-2/neu to the management of node-negative breast cancer (NNBC) could be improved by combining their results. We studied paraffin-embedded primary tumors for p53 (BP-53-12-1) (n=57) and HER2/neu (pAB1) (n=63) from NNBC patients. The results were grouped in a negative (p53(-)/neu(-)) versus a positive group (one or both overexpressed). The association between both groups (negative and positive) and clinicopathologic parameters, S-phase fraction and DNA ploidy, and patients' outcome, was analyzed. In 28% of the tumors p53 was overexpressed, and HER2/neu in 11%. Sixty-five percent (37 out of 57) were p53(-)/neu(-), and 35% overexpressed one (31.5%) or both (3.5%) oncoproteins. Significant correlations were found between p53(-)/neu(-) tumors and age greater than 50 (p=0.003), S-phase fraction lower than 7 (p=0.03), and positive estrogen receptor contents (p=0.049). Actuarial 5-year disease-free and overall survival for p53(-)/neu(-) tumors were 88% and 97%, respectively, versus 50% and 66%, for tumors overexpressing one or both oncoproteins (p=0.004).